Galapagos NV GLPG-NL:Euronext Amsterdam

*Data is delayed | EUR
Last | 11:01 AM CEST
44.46quote price arrow down-0.09 (-0.20%)
Volume
11,258
52 week range
41.30 - 66.28
Loading...
  • Open44.31
  • Day High44.62
  • Day Low44.14
  • Prev Close44.55
  • 52 Week High66.28
  • 52 Week High Date04/07/22
  • 52 Week Low41.30
  • 52 Week Low Date12/06/21

Key Stats

  • Market Cap2,819.13M
  • Shares Out65.73M
  • 10 Day Average Volume176,935.1
  • Dividend-
  • Dividend Yield-
  • Beta0.19
  • YTD % Change-9.67

KEY STATS

  • Open44.31
  • Day High44.62
  • Day Low44.14
  • Prev Close44.55
  • 52 Week High66.28
  • 52 Week High Date04/07/22
  • 52 Week Low41.30
  • 52 Week Low Date12/06/21
  • Market Cap2,819.13M
  • Shares Out65.73M
  • 10 Day Average Volume176,935.1
  • Dividend-
  • Dividend Yield-
  • Beta0.19
  • YTD % Change-9.67

RATIOS/PROFITABILITY

  • EPS (TTM)-0.90
  • P/E (TTM)-49.40
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Galapagos NV

 

Content From Our Affiliates

Profile

MORE
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It...
Paulus Stoffels
Chairman of the Board, Chief Executive Officer
Bart Filius
President, Chief Financial Officer, Chief Operating Officer, Member of the Management Board
Address
Generaal De Wittelaan 3
Malines (mechelen)
2800
Belgium